Drug Trial Radar · NCT01051479
A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer
Last checked: Nov 20, 2026Latest source record: Jul 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Mar 2010
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Wake Forest University Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the investigators ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer.
Conditions
- Esophageal Cancer
Interventions
C11-CholineDrug
15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate our ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer (pre- and post- chemotherapy).Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.